Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test

Yoshihiro Miyashita, MD; Yosuke Hirotsu, PhD; Yuki Nagakubo, MS; Hiroaki Kobayashi, MD; Makoto Kawaguchi, MD; Koki Hata, MD; Ryota Saito, MD; Yumiko Kakizaki, MD; Toshiharu Tsutsui, PhD; Toshio Oyama, MD; Masao Omata, MD

JTO Clinical and Research Reports (Jun 2024)

Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test

Yoshihiro Miyashita, MD,
Yosuke Hirotsu, PhD,
Yuki Nagakubo, MS,
Hiroaki Kobayashi, MD,
Makoto Kawaguchi, MD,
Koki Hata, MD,
Ryota Saito, MD,
Yumiko Kakizaki, MD,
Toshiharu Tsutsui, PhD,
Toshio Oyama, MD,
Masao Omata, MD

Affiliations

Yoshihiro Miyashita, MD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Yosuke Hirotsu, PhD: Genome Analysis Center, Yamanashi Central Hospital, Yamanashi, Japan; Corresponding author. Address for correspondence: Yosuke Hirotsu, PhD, Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, 400-8506, Japan.
Yuki Nagakubo, MS: Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, Yamanashi, Japan
Hiroaki Kobayashi, MD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Makoto Kawaguchi, MD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Koki Hata, MD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Ryota Saito, MD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Yumiko Kakizaki, MD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Toshiharu Tsutsui, PhD: Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan
Toshio Oyama, MD: Pathology Division, Laboratory Department, Yamanashi Central Hospital, Yamanashi, Japan
Masao Omata, MD: Department of Gastroenterology, Yamanashi Central Hospital, Yamanashi, Japan; The University of Tokyo, Tokyo, Japan

Journal volume & issue: Vol. 5, no. 6
p. 100679

Abstract

Read online

Introduction: NSCLC is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as MET exon 14 (METex14) skipping, have been identified in NSCLC, allowing targeted therapy. Tepotinib, a highly selective MET inhibitor, has displayed promise in patients with advanced NSCLC. Nevertheless, challenges arise when identifying treatment strategies for patients with discordant results regarding METex14 skipping detection between diagnostic tests. Methods: We investigated patients with NSCLC and discordant results for METex14 skipping between the Oncomine Dx Target Test (ODxTT) and ArcherMET. Clinical response, adverse events, and the duration of tepotinib treatment were assessed, and statistical analysis was performed. Results: Among the 19 patients deemed METex14 skipping positive by ODxTT, only 10 had concordant results with ArcherMET. The number of METex14 skipping reads detected by ODxTT was significantly lower in discordant cases. Of the 19 patients, 14 received tepotinib, and comparable response and disease control rates were observed in both concordant and discordant cases. The duration of treatment did not significantly differ between the two groups. Conclusions: Our findings suggest that tepotinib has comparable therapeutic effects in patients with METex14 skipping-positive NSCLC irrespective of the concordance of results between ODxTT and ArcherMET. Tepotinib is a possible treatment option for patients with METex14 skipping, even in patients with discordant test results.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords